EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Multizentrische Studie

Phase Ib Study for the Combination of Doxorubicin, Dacarbazine, and Nivolumab as the Upfront Treatment in Patients With Advanced Leiomyosarcoma: A Study by the Spanish Sarcoma Group (GEIS)

Javier Martin-Broto iD, Roberto Diaz-Beveridge, David Moura iD, Rafael Ramos, Javier Martinez-Trufero, Irene Carrasco, Ana Sebio, Enrique González-Billalabeitia iD, Antonio Gutierrez, Javier Fernandez-Jara iD, Laura Hernández-Vargas iD, Josefina Cruz und 2 weitere

Journal of Clinical Oncology · 2025

DOI: 10.1200/jco.24.00358 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Journal of Clinical Oncology, 2025. Verfasst von Javier Martin-Broto und 13 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology Department, Fundacion Jimenez Diaz University Hospital, University Hospital General de Villalba, Madrid, Spain. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Leiomyosarcoma, Nivolumab. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 27 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Doxorubicin, alongside a select group of cytotoxic agents, is capable of inducing an adaptive immune response via a well-established peculiar type of tumor cell death called immunogenic cell death (ICD). We hypothesize that combining doxorubicin and dacarbazine with nivolumab may enhance therapeutic efficacy by exerting synergy in the ICD circuit. We hereby present a phase Ib trial with this combination. PATIENTS AND METHODS Patients with advanced leiomyosarcoma and anthracycline-naïve were eligible. The initial dose level consisted of doxorubicin 75 mg/m 2 once on day 1, once every three weeks, followed by dacarbazine 400 mg/m 2 once on days 1 and 2, once every three weeks, plus nivolumab 360 mg once on day 2, once every 3 weeks, for six courses and then 1 year of nivolumab. A (–1) dose level was the same regimen but with nivolumab 240 mg. A classic 3 + 3 phase-I design was used to determine the recommended phase-II dose (RP2D). Secondary end points included overall response rate, safety profile, survival, and translational research. RESULTS From January 2002 to July 2023, 24 patients were enrolled and 23 were evaluable for efficacy, excluding one patient because of noncompliant dose. All patients were treated with the initial dose level, then the RP2D. Toxicity was mild, with the most frequent being grade 4 toxicity neutropenia (16.7%) and thrombocytopenia (8.3%), while no grade 5 toxicity occurred. The centrally reviewed objective response rate was as follows: partial response 56.5%, stable disease 39.1%, and progression 4.4%. The 6-month progression-free survival (PFS) rate was 80% (95% CI, 63 to 98). Dynamic increases of HMGB1 in blood significantly correlated with longer PFS. CONCLUSION This scheme of doxorubicin, dacarbazine, and nivolumab is feasible and well tolerated. Clinical activity is encouraging and the prognostic impact of HMGB1 supports the relevance of ICD activation. Further clinical research is already underway with this concept in leiomyosarcoma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsLeiomyosarcomaNivolumabAdultAgedFemaleHumansMaleMiddle AgedDacarbazineDoxorubicinFeasibility Studies

Substanzen

DacarbazineDoxorubicinNivolumab

Autor:innen und Institutionen

  • Medical Oncology Department, Fundacion Jimenez Diaz University Hospital, University Hospital General de Villalba, Madrid, Spain.
  • Instituto de Investigacion Sanitaria Fundacion Jimenez Diaz (IIS/FJD; UAM), Madrid, Spain.
  • Medical Oncology Department, Hospital Universitari i Politèctic La Fe, Valencia, Spain.
  • Pathology Department, Hospital Universitari Son Espases, Palma de Mallorca, Spain.
  • Medical Oncology Department, Hospital Universitario Miguel Servet, Zaragoza, Spain.
  • Medical Oncology Department, Hospital Universitario Virgen del Rocio, Sevilla, Spain.

ORCID-Profile: Javier Martin-Broto, David Moura, Enrique González-Billalabeitia, Javier Fernandez-Jara, Laura Hernández-Vargas, Claudia Valverde, Nadia Hindi

Zitieren

APA

Martin-Broto, J., Diaz-Beveridge, R., Moura, D., Ramos, R., Martinez-Trufero, J., Carrasco, I., Sebio, A., González-Billalabeitia, E., Gutierrez, A., Fernandez-Jara, J., Hernández-Vargas, L., Cruz, J., Valverde, C., & Hindi, N. (2025). Phase Ib Study for the Combination of Doxorubicin, Dacarbazine, and Nivolumab as the Upfront Treatment in Patients With Advanced Leiomyosarcoma: A Study by the Spanish Sarcoma Group (GEIS). Journal of Clinical Oncology. https://doi.org/10.1200/jco.24.00358

Vancouver

Martin-Broto J, Diaz-Beveridge R, Moura D, Ramos R, Martinez-Trufero J, Carrasco I, et al. Phase Ib Study for the Combination of Doxorubicin, Dacarbazine, and Nivolumab as the Upfront Treatment in Patients With Advanced Leiomyosarcoma: A Study by the Spanish Sarcoma Group (GEIS). Journal of Clinical Oncology. 2025. doi:10.1200/jco.24.00358

BibTeX
@article{MartinBroto2025,
  author = {Martin-Broto, Javier and Diaz-Beveridge, Roberto and Moura, David and Ramos, Rafael and Martinez-Trufero, Javier and Carrasco, Irene and Sebio, Ana and González-Billalabeitia, Enrique and Gutierrez, Antonio and Fernandez-Jara, Javier and Hernández-Vargas, Laura and Cruz, Josefina and Valverde, Claudia and Hindi, Nadia},
  title = {Phase Ib Study for the Combination of Doxorubicin, Dacarbazine, and Nivolumab as the Upfront Treatment in Patients With Advanced Leiomyosarcoma: A Study by the Spanish Sarcoma Group (GEIS)},
  journal = {Journal of Clinical Oncology},
  year = {2025},
  doi = {10.1200/jco.24.00358}
}
Kostenlos starten →